Phase II studies using tivantinib as a single agent second line therapy in advanced hepatocellular carcinoma (HCC) showed the most significant benefit was obtained for patients expressing high levels of c-Met [73]. The gene discussed is MET; the disease is hepatocellular carcinoma.